Replies to post #121578 on Biotech Values

[investorgold2002]

$720M in the FoB deal, according to the WSJ:

Seems like big amount(even if upfront money is low), since Phase 3 trial just started ?

Also, biosimilar not necessarily biosame (substitutable) ...doubt would be able to capture marketshare

maybe the deal is based on achieving sales milestones